| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
Malignant mesothelioma is a highly refractory disease against conventional therapies. Since major genes responsible for malignant mesothelioma development are primarily tumor suppressor genes, it is very difficult to develop molecular target drugs based on these specific gene mutations. We focused on the BAP1 tumor suppressor gene, which is one the most frequently mutated in malignant mesothelioma, and performed genetic screening to identify genes which show synthetic lethality with this genes (synthetic lethality means that simultaneous alterations of two genes induce cell death of cancer cells but not normal cells). We found that several interesting genes show synthetic lethality with BAP1 mutation and can be applied for promising targets for new molecular target therapy against malignant mesothelioma.
|
